Stifel initiates coverage of Innovative Industrial Properties and Immatics with Buy ratings

what happened

Stifel has begun coverage of Innovative Industrial Properties with a Buy rating and a price target of $56.25. The target implies a 9.1% gain from the October 13 close of $51.55. According to the analyst note, the company has a solid balance sheet: its net debt plus preferred to enterprise value ratio stands at 31.7%, versus a peer average of 38.6%, and no debt matures before 2028.

Stifel also points to a 14.7% dividend yield, compared with a sector average of 6.6%, and a projected 100.1% payout ratio for 2027.

Stifel has also initiated coverage of Immatics with a Buy rating and a $15.00 price target. The target implies a 119.6% upside from the October 13 close of $6.83. The analysts highlight progress in the Phase 3 SUPRAME trial of anzu-cel in cutaneous melanoma after immune checkpoint inhibitor therapy, and an anticipated launch in early 2028.

why it matters

A new initiation from a major brokerage draws attention to both stocks: one case rests on balance sheet strength and dividends, the other on clinical data and product positioning. Analyst price targets are not a forecast of where the shares will trade.

tags

instruments